Fosun International Limited's Henlius recently announced the presentation of updated phase 2 results and the design for a phase 3 clinical trial of their anti-HER2 monoclonal antibody, HLX22, targeting first-line HER2-positive gastric cancer. The announcement was made at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The phase 2 study results highlight the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy, with over two years of follow-up data. The phase 3 trial, HLX22-GC-301, will compare HLX22 with the current standard of care therapy, enrolling approximately 550 patients globally. The trial will evaluate progression-free survival and overall survival as dual primary endpoints. Additionally, HLX22's scope has expanded to include breast cancer, with a phase 2 trial for HER2-low, hormone receptor-positive breast cancer underway in China.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。